Dotinurad

1285572-51-1

CAS-Nr.: 1285572-51-1

Englisch Name:: Dotinurad

Synonyma:: Dotinurad;Dotinurad (FYU-981);3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole;(3,5-Dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)methanone;(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone;Methanone, (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)-;uricosuric,Inhibitor,Dotinurad,URAT1,urate,reabsorption,SLC22A12,Urate transporter 1,inhibit,transporter

CBNumber:: CB44667832

Summenformel:: C14H9Cl2NO4S

Molgewicht:: 358.2

MOL-Datei:: 1285572-51-1.mol

Request For Quotation

Eigenschaften Sicherheit Verwendungswort Produktionsfirma 64

Dotinurad Eigenschaften

Schmelzpunkt:: 188 - 191°C

Siedepunkt:: 614.8±55.0 °C(Predicted)

Dichte: 1.662±0.06 g/cm3(Predicted)

storage temp.: -20°C Freezer, Under inert atmosphere

Löslichkeit: Chloroform (Slightly, Sonicated), DMSO (Sparingly)

pka: 4.60±0.25(Predicted)

Aggregatzustand: Solid

Farbe: White to Off-White

Sicherheit

Dotinurad Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Dotinurad is an organic compound with the chemical Name (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone. This compound is a newer urate-lowering agent that suppresses uric acid reabsorption through the selective inhibition of urate transporter 1 (URAT1) in the proximal renal tubules, and it was first approved in Japan in 2020 for the treatment of hyperuricemia, irrespective of gout[1].

Verwenden

Dotinurad is a useful drug for treating hyperuricemia and gout.

Dotinurad Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Dotinurad Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 64)Lieferanten

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	19892	58
Henan Alfa Chemical Co., Ltd	+8618339805032	alfa4@alfachem.cn	China	13094	58
Nextpeptide Inc	+86-0571-81612335 +8613336028439	sales@nextpeptide.com	China	19915	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6393	58
Huadong Medicine (Xi'an)Bodyguard Pharmaceutical Co.,Ltd.	+86-029-86185165 +8618629664246	guoyuan@eastchinapharm.com	China	1615	58
Hangzhou MolCore BioPharmatech Co.,Ltd.	+86-057181025280; +8617767106207	sales@molcore.com	China	49739	58
Zibo Hangyu Biotechnology Development Co., Ltd	+86-0533-2185556 +8617865335152	Mandy@hangyubiotech.com	China	10978	58
Arizest(Shanghai)Pharmatech Co., Ltd	+86-021-60753300	3652837972@qq.com	China	220	58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.	+86-18600796368 +86-18600796368	sales@sjar-tech.com	China	49	58
Wuhan HSN Pharmaresearch CO., LTD.	027-63499089 18086100502	linwell@126.com	China	201	50

Dotinurad
Methanone, (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)-
Dotinurad (FYU-981)
(3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone
uricosuric,Inhibitor,Dotinurad,URAT1,urate,reabsorption,SLC22A12,Urate transporter 1,inhibit,transporter
(3,5-Dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)methanone
3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole
1285572-51-1
API